-
公开(公告)号：US20160264654A1
公开(公告)日：2016-09-15
申请号：US15161893
申请日：2016-05-23
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Russell P. ROTHER , Douglas L. SHERIDAN , Paul P. TAMBURINI , Yuchun ZHANG
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/461 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Abstract translation: 本公开尤其涉及结合C5a的抗体或其抗原结合片段以及在用于治疗或预防补体相关病症例如但不限于非典型溶血性尿毒症综合征的方法中使用抗体 ，年龄相关性黄斑变性，类风湿性关节炎，败血症，严重烧伤，抗磷脂脂质综合征，哮喘，狼疮肾炎，古德帕斯彻综合征和慢性阻塞性肺疾病。
-
公开(公告)号：US20170369562A1
公开(公告)日：2017-12-28
申请号：US15700805
申请日：2017-09-11
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Russell P. ROTHER , Camille Bedrosian , Stephen P. Squinto , Leonard Bell
CPC classification number: C07K16/18 , A61K9/0019 , A61K38/00 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/24 , C07K2317/34
Abstract: The present disclosure relates to, inter alia, compositions containing an inhibitor of human complement and use of the compositions in methods for treating or preventing complement-associated disorders. In some embodiments, the inhibitor is chronically administered to patients. In some embodiments, the inhibitor is administered to a patient in an amount and with a frequency to maintain systemic complement inhibition and prevent breakthrough. In some embodiments, the compositions contain an antibody, or antigen-binding fragment thereof, that binds to a human complement component C5 protein or a fragment of the protein such as C5a or C5b.
-
公开(公告)号：US20160009803A1
公开(公告)日：2016-01-14
申请号：US14739862
申请日：2015-06-15
Applicant: ALEXION PHARMACEUTICALS, INC.
Inventor： Russell P. ROTHER , Yan YAN
IPC: C07K16/28
CPC classification number: C07K16/2803 , A61K39/39541 , A61K2039/505 , C07K16/2887 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/54 , C07K2317/55 , C07K2317/565 , C07K2317/622 , C07K2317/626 , C07K2317/732 , C07K2317/76 , A61K2300/00
Abstract: The present disclosure relates to anti-CD200 antibodies and to use of the antibodies in methods for treating autoimmune disorders and cancer. Also featured are biomarkers for use in selecting or prescribing a treatment modality for a patient with an autoimmune disorder and/or cancer. In addition, the disclosure features methods of treatment using an anti-CD200 antibody in combination with one or more additional therapeutic agents such as an anti-CD20 therapeutic agent.
-
4.发明申请REAGENTS AND METHODS FOR DETECTING PNH TYPE II WHITE BLOOD CELLS AND THEIR IDENTIFICATION AS RISK FACTORS FOR THROMBOTIC DISORDERS 审中-公开用于检测PNH II型白细胞的试剂和方法及其作为血栓病症风险因子的鉴定公开(公告)号：US20140286962A1
公开(公告)日：2014-09-25
申请号：US14219218
申请日：2014-03-19
Applicant: ALEXION PHARMACEUTICALS, INC.
Inventor： Mayur MOVALIA , Andrea ILLINGWORTH , Susan FAAS MCKNIGHT , Russell P. ROTHER
IPC: G01N33/50 , A61K31/727 , C07K16/40 , A61K31/56 , A61K38/19 , A61K38/48 , A61K31/352 , A61K35/14
CPC classification number: G01N33/5094 , A61K31/352 , A61K31/56 , A61K31/727 , A61K35/19 , A61K38/196 , A61K38/4886 , C07K16/40 , G01N33/56972 , G01N33/6893 , G01N2800/226
Abstract: The disclosure relates to methods for detecting PNH Type II cell populations in biological samples as well as methods for determining whether a patient is at an increased risk for developing thrombocytopenia or thrombosis based on the percentage of PNH Type II cells in the patient's blood. The disclosure also features reagents and conjugates for use in the methods.
Abstract translation: 本公开涉及用于检测生物样品中PNH II型细胞群的方法，以及用于基于患者血液中PNH II型细胞的百分比来确定患者是否处于发生血小板减少症或血栓形成的风险增加的方法。 本公开还涉及用于该方法的试剂和共轭物。
-
公开(公告)号：US20200207842A1
公开(公告)日：2020-07-02
申请号：US16569203
申请日：2019-09-12
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Russell P. ROTHER , Douglas L. SHERIDAN , Paul P. TAMBURINI , Yuchun ZHANG
Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
-
Patent Agency Ranking
公开(公告)号：US20170267751A1
公开(公告)日：2017-09-21
申请号：US15476644
申请日：2017-03-31
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Russell P. ROTHER , Hao WANG , Zhen ZHONG
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K2039/505
Abstract: Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
-
7.发明申请TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT 有权通过补充抑制剂治疗寄生虫病人血液白血病患者公开(公告)号：US20160244516A1
公开(公告)日：2016-08-25
申请号：US15148839
申请日：2016-05-06
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Leonard BELL , Russell P. ROTHER
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K9/0019 , A61K31/7105 , A61K38/00 , A61K2039/505 , C07K2317/24 , C07K2317/51 , C07K2317/515 , C07K2317/565
Abstract: Eculizumab, a humanized monoclonal antibody against C5 that inhibits terminal complement activation, showed activity in a preliminary 12-week open-label trial in a small cohort of patients with paroxysmal nocturnal hemoglobinuria (PNH). The present study examined whether chronic eculizumab therapy could reduce intravascular hemolysis, stabilize hemoglobin levels, reduce transfusion requirements, and improve quality of life in a double-blind, randomized, placebo-controlled, multi-center global Phase III trial. It has been found that eculizumab stabilized hemoglobin levels, decreased the need for transfusions, and improved quality of life in PNH patients via reduced intravascular hemolysis. Chronic eculizumab treatment appears to be a safe and effective therapy for PNH.
Abstract translation: 厄洛珠单抗是抑制末端补体激活的C5的人源化单克隆抗体，在阵发性夜间血红蛋白尿（PNH）患者的小队列中，在初步的12周开放标签试验中显示出活性。 本研究检查了在双盲，随机，安慰剂对照，多中心全球III期试验中，慢性eculizumab治疗是否可以减少血管内溶血，稳定血红蛋白水平，降低输血需求，提高生活质量。 已经发现，通过减少血管内溶血，厄库珠单抗稳定了血红蛋白水平，降低了输血的需要，并改善PNH患者的生活质量。 慢性eculizumab治疗似乎是PNH的安全有效的治疗方法。
-
公开(公告)号：US20150183859A1
公开(公告)日：2015-07-02
申请号：US14657176
申请日：2015-03-13
Applicant: ALEXION PHARMACEUTICALS, INC.
Inventor： Russell P. ROTHER , Douglas L. SHERIDAN , Paul P. TAMBURINI , Yuchun ZHANG
IPC: C07K16/18
CPC classification number: C07K16/18 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K2039/505 , C07K16/28 , C07K16/461 , C07K2317/21 , C07K2317/24 , C07K2317/31 , C07K2317/33 , C07K2317/34 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94
Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
Abstract translation: 本公开尤其涉及结合C5a的抗体或其抗原结合片段以及在用于治疗或预防补体相关病症例如但不限于非典型溶血性尿毒症综合征的方法中使用抗体 ，年龄相关性黄斑变性，类风湿性关节炎，败血症，严重烧伤，抗磷脂脂质综合征，哮喘，狼疮肾炎，古德帕斯彻综合征和慢性阻塞性肺疾病。
-
公开(公告)号：US20230159627A1
公开(公告)日：2023-05-25
申请号：US17849793
申请日：2022-06-27
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Russell P. ROTHER , Douglas L. SHERIDAN , Paul P. TAMBURINI , Yuchun ZHANG
CPC classification number: C07K16/18 , A61K47/60 , C07K14/472 , C07K16/461 , C07K16/28 , A61K39/3955 , A61K45/06 , A61K2039/505
Abstract: The present disclosure relates to, inter alia, antibodies, or antigen-binding fragments thereof, that bind to C5a and to use of the antibodies in methods for treating or preventing complement-associated disorders such as, but not limited to, atypical hemolytic uremic syndrome, age-related macular degeneration, rheumatoid arthritis, sepsis, severe burn, antiphospho lipid syndrome, asthma, lupus nephritis, Goodpasture's syndrome, and chronic obstructive pulmonary disease.
-
公开(公告)号：US20190309053A1
公开(公告)日：2019-10-10
申请号：US16190601
申请日：2018-11-14
Applicant: Alexion Pharmaceuticals, Inc.
Inventor： Russell P. ROTHER , Hao WANG , Zhen ZHONG - DECEASED
IPC: C07K16/18
Abstract: Methods of prolonging survival of allotransplanted cells, tissues or organs are presented. These methods are directed to administering to the allotransplant recipient an inhibitor of complement activity together with one or more immunosuppressants. The inhibitor of complement activity is administered chronically. These methods have been determined to aid in preventing chronic rejection of allografts. These methods can additionally be used in cases in which the recipient has been presensitized to the allograft or in which there is an ABO mismatch between the allograft and the recipient.
-
-
-
-
-
-
-
-
-
Search Results
18
records
(took 0.026 seconds)
